Cargando…
Rituximab Hypersensitivity: From Clinical Presentation to Management
Rituximab is a chimeric monoclonal antibody (mAb) against CD20 molecule which is expressed on human B cells. It has been used for the treatment of various lymphoid malignancies, lymphoproliferative diseases, and rheumatologic disorders. Rituximab is generally well tolerated. However, increased use o...
Autores principales: | Fouda, Ghada E., Bavbek, Sevim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508176/ https://www.ncbi.nlm.nih.gov/pubmed/33013416 http://dx.doi.org/10.3389/fphar.2020.572863 |
Ejemplares similares
-
Successful Desensitization of a Patient with Rituximab Hypersensitivity
por: Ataca, Pinar, et al.
Publicado: (2015) -
Editorial: Biomarkers in Drug Hypersensitivity
por: Agúndez, José A. G., et al.
Publicado: (2017) -
Hypersensitivity to Carboplatin in Children with Malignancy
por: Ruggiero, Antonio, et al.
Publicado: (2017) -
Rituximab Therapy for Primary Sjögren’s Syndrome
por: Chen, Yi Han, et al.
Publicado: (2021) -
Rituximab Concentration Varies in Patients With Different Lymphoma Subtypes and Correlates With Clinical Outcome
por: Liu, Shu, et al.
Publicado: (2022)